HIPGEN: a randomized, multicentre phase III study using intramuscular PLacenta-eXpanded stromal cells therapy for recovery following hip fracture arthroplasty: a study design

AIMS: The aim of the HIPGEN consortium is to develop the first cell therapy product for hip fracture patients using PLacental-eXpanded (PLX-PAD) stromal cells. METHODS: HIPGEN is a multicentre, multinational, randomized, double-blind, placebo-controlled trial. A total of 240 patients aged 60 to 90 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Tobias, Costa, Matthew L., Ofir, Racheli, Parolini, Ornella, Geissler, Sven, Volk, Hans-Dieter, Eder, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2022
Materias:
Hip
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044085/
https://www.ncbi.nlm.nih.gov/pubmed/35451865
http://dx.doi.org/10.1302/2633-1462.34.BJO-2021-0156.R1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044085/
https://www.ncbi.nlm.nih.gov/pubmed/35451865
http://dx.doi.org/10.1302/2633-1462.34.BJO-2021-0156.R1

Ejemplares similares